Iron deficiency anemia treatment market to reach $16.17B by 2030

The iron deficiency anemia treatment market is projected to grow from $8.83 billion in 2025 to $16.17 billion by 2030, driven by rising anemia cases, chronic kidney disease and broader use of iron therapies. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Iron deficiency anemia treatment is moving from a steady-care category to a faster-growing global market as diagnosis expands and more patients need iron replacement therapy. - The market outlook matters because chronic kidney disease, aging populations and broader access to treatment are increasing demand for oral, intravenous and injectable iron options.

What happened: - The Business Research Company said the iron deficiency anemia treatment market was worth $8.83 billion in 2025. - The market is forecast to rise to $9.98 billion in 2026, implying 13.0% growth. - The market is projected to reach $16.17 billion by 2030, at a 12.8% CAGR. - The report was released Aug. 13, 2026, from London. - The company published a free sample of the report at More information.

The details: - Demand is being driven by more iron deficiency disorders, more anemia diagnosis in chronic illness, wider use of hospital treatment protocols and greater availability of oral iron supplements. - The report also points to growing awareness of anemia management as a support for market expansion. - The forecast to 2030 reflects expected gains from a larger elderly population, faster iron replenishment therapies, more injectable iron use and personalized care models. - Emerging trends include more intravenous iron treatments, higher-bioavailability products, patient-centric anemia therapies, outpatient and home-based administration, and better monitoring and adherence tools. - Iron deficiency anemia treatment includes oral and intravenous iron supplementation and dietary changes aimed at restoring iron levels and easing anemia symptoms. - Effective treatment can improve oxygen transport, reduce fatigue and support overall patient wellbeing. - The full report is available at The full report. - North America held the largest market share in 2025. - Asia-Pacific is expected to post the fastest growth over the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report package adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and technology and future-trend analysis.

Between the lines: - Chronic kidney disease is a major demand driver because anemia often accompanies CKD and can worsen fatigue and oxygen delivery. - AstraZeneca projected in April 2024 that about 16.5% of people across eight countries, including the U.S., U.K., China and Australia, will have CKD by 2032. - AstraZeneca also projected advanced-stage CKD cases could rise by up to 59.3%. - That forecast suggests the iron deficiency anemia treatment market is benefiting from a broader renal-care burden, not just standalone anemia cases.

What's next: - The market is expected to keep shifting toward faster, more convenient and more personalized iron replacement therapies through 2030. - Growth in outpatient and home-based treatment could make administration easier and expand use beyond hospital settings. - Better monitoring and adherence tools may become more important as therapies diversify and patient management becomes more distributed.

The bottom line: - Iron deficiency anemia treatment is on track for double-digit growth through 2030, with CKD, aging populations and treatment innovation shaping the next phase of demand.